Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

BACKGROUND: Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bone
Main Authors: Swallow, Elizabeth A., Aref, Mohammad W., Metzger, Corinne E., Sacks, Spencer, Lehmkuhler, Demi R., Chen, Neal, Hammond, Max A., Territo, Paul R., Nickolas, Thomas L., Moe, Sharon M., Allen, Matthew R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6708715/
https://ncbi.nlm.nih.gov/pubmed/31299384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2019.07.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados